Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Inhibition of Nuclear Entry of MAPK Cascade Proteins as a Novel Mechanism for Treating Cancer
Yeda R&D Co. Ltd Israel flag Israel
Abstract ID: 1446
The ability to regulate cellular localization of a biological component is important for many functions such as gene therapy, protection from toxic chemicals, transport of anti-cancer agents, and...
Contact
Participants
You
Email me a copy of this message
Introduction/Background

The ability to regulate cellular localization of a biological component is important for many functions such as gene therapy, protection from toxic chemicals, transport of anti-cancer agents, and possibly preventing nuclear translocation of oncogenes. To ensure accurate cellular functioning, the spatial distribution of proteins needs to be delicately regulated and coordinated. This is particularly apparent in many signalling proteins that dynamically and rapidly change their localization upon extracellular stimulation.

Aims/Hypothesis

The present invention provides peptides that may be used to regulate the nuclear translocation of proteins that endogenously comprise such nuclear translocation signals.

Results

The current invention identifies a 3-amino acid domain (Ser-Pro-Ser, SPS), which is a nuclear translocation signal present in signalling proteins such as extracellular signal-regulated kinase (ERK2) protein, SMAD3 and mitogen-activated protein kinase 1 (MEK1). SPS participates in nuclear translocation upon extracellular stimulation. Since several of these proteins are involved in the regulation of cellular proliferation and oncogenic transformation, the SPS domain can compete with the translocation machinery and therefore prevent the translocation of the proteins into the nucleus. As was shown in animal models, inhibiting this mechanism has an advantage over other ways of inhibition as it doesn't lead to a negative feedback loop which may enhance the production of the protein.

Conclusion

We have elucidated peptide sequences for efficient inhibition of nuclear translocation of proteins.

Relevance/Opportunity

Please enquire quoting reference no. 1446 regarding licensing or codevelopment partnerships.
GO PREMIUM TO GET PATENT INFORMATION
FEATURED
Last Updated May 2015
Technology Type MECHANISM
Phase of Development PRECLINICAL
CORPORATION